CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 153 enrolled
Drug / intervention
Continuous Positive Airway Pressure (CPAP) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00607893
NCT00607893N/ACompleted

Oxidative Stress in Sleep Apnea and Cardiac Disease

Case Western Reserve University·interventional·Posted Feb 6, 2008·Updated Sep 15, 2017

In Brief

A clinical study evaluating Continuous Positive Airway Pressure (CPAP) and Sham CPAP for Sleep Apnea Syndromes and 2 related conditions. Completed, enrolled 153 participants across 1 site.

Detailed Summary

Sleep-disordered breathing (SDB) is a condition in which a person experiences frequent breathing pauses during sleep, also known as sleep apnea. There is evidence that the recurrent sleep arousal and associated shortage of oxygen in the body may increase risk for cardiovascular disease (CVD). It is believed that treatment with continuous positive airway pressure (CPAP) may reduce certain risk factors for heart disease, including markers of inflammation and oxidative stress. This study will evaluate the effectiveness of CPAP in reducing CVD risk factors in people with SDB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartSep 1, 2006
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.4 years ago

Interventions

Continuous Positive Airway Pressure (CPAP)device

Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.

Sham CPAPdevice

Participants will use the lower pressure CPAP every night for 8 weeks.